Sionna Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-61.69	-47.26	-40.24
Depreciation & Amortization	0.67	0.58	0.12
Loss (Gain) From Sale of Investments	-3	-0.68	-0.4
Stock-Based Compensation	3.71	2.26	1.69
Other Operating Activities	10.6	2.18	-
Change in Accounts Payable	0.47	0.16	-1.51
Change in Other Net Operating Assets	-3.54	-0.95	4.28
Operating Cash Flow	-52.79	-43.7	-36.07
Capital Expenditures	-0.03	-1.12	-1.87
Investment in Securities	-126.89	28.47	-27.39
Investing Cash Flow	-126.91	27.35	-29.26
Issuance of Common Stock	0.14	0.03	0.06
Other Financing Activities	-2.5	-	-0.2
Financing Cash Flow	178.97	0.03	110.86
Net Cash Flow	-0.73	-16.32	45.52
Free Cash Flow	-52.81	-44.82	-37.94
Free Cash Flow Per Share	-13.69	-15.28	-14.72
Levered Free Cash Flow	-40.48	-30.14	-
Unlevered Free Cash Flow	-40.48	-30.14	-
Change in Net Working Capital	0.73	0.41	-

Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q